Business Context and Reporting Period
This Form 8-K, filed on August 2, 2016, reports the financial results for AmerisourceBergen Corporation (now Cencora) for the fiscal quarter ended June 30, 2016. The company is a global pharmaceutical sourcing and distribution services provider. The filing incorporates a news release detailing third-quarter fiscal 2016 performance, segment results, and updated guidance.
Key Financial Metrics
| Metric | Q3 FY2016 (GAAP) | Q3 FY2015 (GAAP) | Change |
|---|---|---|---|
| Revenue | $36.9 billion | $34.2 billion | +7.7% |
| Gross Profit | $1.1 billion | $0.9 billion | +24.3% |
| Gross Margin | 3.00% | 2.60% | +40 bps |
| Operating Income | $526.6 million | $332.6 million | +58.3% |
| Operating Margin | 1.43% | 0.97% | +46 bps |
| Net Income | $349.8 million | $214.2 million | +63.3% |
| Diluted EPS (GAAP) | $1.56 | $0.89 | +75.3% |
| Adjusted Diluted EPS | $1.37 | $1.20 | +14.2% |
| Free Cash Flow (YTD) | $1.8 billion (9 months) | $2.8 billion (9 months) | N/A |
Balance Sheet Highlights (as of June 30, 2016):
- Cash and Cash Equivalents: $1.9 billion
- Total Assets: $31.9 billion
- Long-term Debt: $3.8 billion
- Current Liabilities: $24.0 billion
Material Changes vs. Prior Period
- Revenue Growth: Driven by an 8.0% increase in Pharmaceutical Distribution revenue and a 2.8% increase in the "Other" segment. The Specialty Group (ABSG) saw a 20.2% revenue increase.
- GAAP Profit Surge: The 75.3% increase in GAAP EPS was significantly influenced by a $121.0 million gain from antitrust litigation settlements and a reduction in LIFO expense compared to the prior year.
- Adjusted Performance: On an adjusted basis (excluding litigation gains, LIFO, and acquisition costs), operating income grew 8.4% and adjusted EPS grew 14.2%, reflecting organic growth and contributions from recent acquisitions (PharMEDium and MWI Veterinary Supply).
- Share Count: Diluted weighted average shares outstanding declined 6.4% year-over-year due to share repurchases.
Guidance, Outlook, and Risks
Updated Fiscal 2016 Guidance (Adjusted Basis):
- Adjusted Diluted EPS: $5.52 to $5.57 (raised from prior expectations).
- Revenue Growth: Approximately 8%.
- Operating Income Growth: 5% to 6%.
- Free Cash Flow: $1.9 billion to $2.1 billion.
- Capital Expenditures: Approximately $400 million.
Preliminary Fiscal 2017 Outlook:
- Adjusted diluted EPS expected to grow 4% to 6% above the midpoint of the updated FY2016 guidance.
- Management anticipates continued headwinds, including high single-digit deflation on generic products.
Key Risks and Contingencies:
- Generic Deflation: Ongoing price pressure in the generic pharmaceutical market.
- Regulatory Changes: Potential impacts from Medicare Part B reimbursement changes and healthcare regulatory shifts.
- Customer Concentration: Risks associated with the strategic relationship with Walgreens Boots Alliance, Inc.
- Integration Risks: Challenges in integrating recent acquisitions (MWI, PharMEDium).
Investor Verification Checklist
- Non-GAAP Reconciliations: Verify the specific impact of the $121 million antitrust litigation gain and LIFO expense adjustments on GAAP vs. Adjusted EPS.
- Warrant Coverage: Review the status of the 2017 Warrants issued to Walgreens Boots Alliance and the company's hedging strategy (capped calls) to mitigate dilution.
- Segment Margins: Analyze the divergence between the low-margin Pharmaceutical Distribution segment (1.16% operating margin) and the higher-margin "Other" segment (5.23% operating margin).
- Cash Flow Utilization: Confirm the allocation of free cash flow between debt reduction, dividends, and the $350 million regular share repurchase program.
- Future Headwinds: Assess the sensitivity of the FY2017 guidance to the projected "high single digit" generic deflation rate.